Shares of Schrodinger, a company that has spent years building physics-based drug discovery software, fell as much as 8.3 percent within hours of Anthropic's announcement on June 30. That is not a coincidence of market timing. It is a direct read on how seriously investors took Anthropic's decision to stop selling AI tools to pharmaceutical companies and start running its own drug discovery lab instead.

A New Product Launch With an Unusual Twist

At an event called "The Briefing: AI for Science" in San Francisco, Anthropic unveiled Claude Science, a new standalone product the company is positioning alongside Claude Code and Claude Cowork as one of its three flagship offerings. That placement matters. Anthropic did not fold this into an existing plugin or a minor feature update. According to MIT Technology Review's coverage of the launch, elevating Claude Science to the same tier as its coding and enterprise products signals that the company wants scientific research treated as a core pillar of its business, not a side experiment.

The bigger surprise came in the same announcement. Alongside the product launch, Anthropic said it would begin running its own pre-clinical drug discovery programs, focused specifically on neglected diseases, the category of illnesses that carry a heavy global health burden but that major pharmaceutical companies routinely skip because they are not commercially attractive. A tech company simultaneously selling research software to drugmakers and quietly becoming one is an unusual structure, and Anthropic's own executives addressed the tension directly rather than dodging it.

What Claude Science Actually Does

Claude Science is not a new AI model. It is a research environment built on top of Anthropic's existing Claude models, designed to unify tools and databases that scientists currently have to juggle separately. The platform integrates more than 60 pre-configured scientific databases spanning genomics, proteomics, single-cell analysis, structural biology, and cheminformatics into one workspace. Researchers can pull in literature, run analyses, and review calculations without constantly switching between disconnected systems like PubMed, Jupyter notebooks, and R scripts.

The platform's central AI assistant can spawn specialized sub-agents to handle specific research tasks, and it can hand off work to custom agents that researchers build for their own particular problems. It can also render scientific outputs directly, including protein structures and chemical models, while showing the underlying code and workflow that produced them. Claude Science is available now in beta to all Claude Pro, Max, Team, and Enterprise subscribers, a notably broad rollout for a specialized scientific tool rather than a narrow enterprise-only release.

Why Anthropic Is Running Its Own Drug Lab

Eric Kauderer-Abrams, Anthropic's head of life sciences, explained the reasoning at the event in terms that read more like an engineering philosophy than a corporate mission statement. "We're doing this because we believe first and foremost that to build the right models, products and tools to accelerate the industry, we need to live it along with all of you," he said, adding that the company believes in "the power of tight feedback loops" and that there is no substitute for having its own hands-on experience developing drugs alongside the customers it is trying to sell to.

Jonah Cool, Anthropic's head of life sciences partnerships, framed the neglected-disease focus as central to how Anthropic wants to build and sell its life sciences tools going forward. Notably, Kauderer-Abrams did not say what would happen if the internal program actually produces a promising drug candidate, nor did the company disclose a timeline or budget for the effort. That is a real gap. Running a drug discovery program is expensive and slow by nature, and a company that has not committed to funding or a schedule is signaling this as exploratory rather than a fully resourced bet.

The Market Didn't Wait to React

Investors treated the announcement as a genuine competitive threat rather than a public relations exercise. Beyond Schrodinger's sharp intraday drop, Recursion Pharmaceuticals, a company that pairs AI with automated robotic labs to analyze biological data, saw its own shares swing sharply before partially recovering. When a software company's product launch moves the stock price of established drug discovery firms within the same trading session, it tells you the market believes Anthropic's entry changes the competitive math, not just the marketing landscape.

Anthropic named early customers for Claude Science, including Novo Nordisk and the Allen Institute, and is running a grant program offering up to 30,000 dollars in credits for as many as 50 research projects, with applications closing July 15 and recipients announced by July 31. That grant structure functions as a fast, low-cost way to generate case studies and goodwill inside the research community before the product fully matures.

A Three-Way Race Already Underway

Anthropic is a late entrant here, not a pioneer. Google's DeepMind subsidiary, Isomorphic Labs, is reportedly nearing clinical entry for drug candidates designed by its own AI systems, and Google separately offers "Gemini for Science," a platform bundling AlphaFold and AlphaGenome with more than 30 life sciences databases. OpenAI entered the space in April with GPT-Rosalind, a model specialized in biological reasoning, though it remains available only to a limited set of vetted enterprise customers following a safety review.

That competitive backdrop reframes what Anthropic is really doing. This is not a novel bet on AI curing disease so much as a company trying to avoid being the only major AI lab without a life sciences offering while its two biggest rivals already have products in the market or nearing clinical milestones.

The Timing Nobody's Saying Out Loud

Anthropic has already filed confidential paperwork with the U.S. Securities and Exchange Commission for an initial public offering, and reporting from Yahoo Finance frames Claude Science as part of a broader push to build additional, vertically specialized revenue streams ahead of that listing. The company has said it expects its first profitable quarter, and new enterprise contracts with pharmaceutical companies would help sustain that profitability as the temporary surge in agentic token spending that boosted revenue earlier in the year cools off.

None of that undercuts the genuine humanitarian case for prioritizing neglected diseases, or the public benefit corporation structure Anthropic points to as justification for putting research value ahead of short-term returns. But the timing, a major new product launch and a self-funded drug discovery program, arriving in the exact window when Anthropic needs a diversified, defensible revenue story for prospective public investors, is not something the company volunteered as context. It is worth remembering when weighing how much of this is mission and how much is a well-timed pitch to Wall Street.